Phase III progression-free survival data from the MONARCH 2 study presented at the American Society of Clinical Oncology meeting put Eli Lilly & Co. in a good position to file the CDK4/6 inhibitor abemaciclib in the second quarter as planned, though a different release by rival Pfizer Inc.'s Ibrance raised questions about whether the class will be able to show an overall survival benefit.
ASCO Upsets CDK4/6 Class: Strong Data For Lilly's Abemaciclib, But Pfizer's Ibrance Disappoints
CDK4/6 inhibitors offer impressive progression-free survival data in breast cancer, but lack of overall survival data may mean the class will be relegated to the second-line setting.
More from Clinical Trials
• By
Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from R&D
• By
Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.